Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 8NIH 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Breast Neoplasms 6Breast Neoplasms, Male 3Testicular Neoplasms 2Testicular Germ Cell Tumor 2Lymphoma, Mantle-Cell 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma 2Uterine Cervical Neoplasms 1Teratoma 1Seminoma 1Sarcoma, Synovial 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Renal Pelvis and Ureter Urothelial Carcinoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neutropenia 1Neurofibrosarcoma 1Neuroblastoma 1Neoplasms, Plasma Cell 1Neoplasms 1Multiple Myeloma 1Lymphoma, Follicular 1Lymphoma, AIDS-Related 1Inflammatory Breast Neoplasms 1Hodgkin Disease 1Hematologic Neoplasms 1Endodermal Sinus Tumor 1Central Nervous System Neoplasms 1Carcinoma, Embryonal 1

Interventions

Rituximab 33Cyclophosphamide 23Filgrastim 18Peripheral Blood Stem Cell Transplantation 16Etoposide 13fludarabine phosphate 12Vincristine 12Prednisone 11Bortezomib 11sargramostim 10Radiotherapy 10Doxorubicin 8Cytarabine 8Cyclosporine 8Vorinostat 7Lenalidomide 7Cisplatin 7Biopsy 7tanespimycin 6Melphalan 6Magnetic Resonance Spectroscopy 6Ifosfamide 6bryostatin 1 5alvocidib 5aldesleukin 5Specimen Handling 5Methylprednisolone 5Methotrexate 5Interferon-alpha 5Gemcitabine 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Lymphoma, Follicular × pegfilgrastim × Clear all
NCT00086944 2013-01-24

Oblimersen, Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

National Cancer Institute (NCI)

Phase 1/2 Completed
25 enrolled
Lymphoid

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡